NPY(1)R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression

OBJECTIVE: PPARα/γ dual agonists have been in clinical development for the treatment of metabolic diseases including type 2 diabetes and dyslipidemia. However, severe adverse side effects led to complications in clinical trials. As most of the beneficial effects rely on the compound activity in adip...

Descripción completa

Detalles Bibliográficos
Autores principales: Wittrisch, Stefanie, Klöting, Nora, Mörl, Karin, Chakaroun, Rima, Blüher, Matthias, Beck-Sickinger, Annette G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931124/
https://www.ncbi.nlm.nih.gov/pubmed/31918918
http://dx.doi.org/10.1016/j.molmet.2019.11.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931124/
https://www.ncbi.nlm.nih.gov/pubmed/31918918
http://dx.doi.org/10.1016/j.molmet.2019.11.009

Ejemplares similares